Type 1 diabetes results from autoimmune destruction of pancreatic beta cells causing absolute insulin deficiency and hyperglycemia. Type 2 diabetes involves insulin resistance and progressive beta cell failure. Both lead to microvascular (retinopathy, nephropathy, neuropathy) and macrovascular (atherosclerosis) complications.
Compare pathophysiology: Type 1 presents acutely with DKA; Type 2 develops insidiously with metabolic syndrome. Understand glycemic targets and A1C as markers of long-term glucose control.
Type 1 diabetes is not purely genetic—environmental triggers are required. Type 2 is not simply 'lifestyle disease'—genetic predisposition is equally important. Hyperglycemia itself drives complications independent of underlying etiology.
You already understand that glucose homeostasis is a tightly regulated feedback loop: rising blood glucose triggers beta-cell insulin secretion, insulin drives glucose into cells, and glucose falls back to baseline. Diabetes is what happens when this loop breaks — but the break occurs in fundamentally different places in Type 1 versus Type 2, leading to the same symptom (hyperglycemia) by very different mechanisms.
Type 1 diabetes is an autoimmune disease. The immune system mounts an attack on pancreatic beta cells, progressively destroying the source of insulin itself. Once enough beta cells are lost, the loop has no output: no insulin signal means GLUT4 does not translocate to muscle and fat cell membranes, glycogen synthesis halts, and glucagon — now unopposed — drives continuous hepatic glucose output. Blood glucose climbs without a physiological brake. Because cells cannot take up glucose, they behave as if starving: fat is mobilized, fatty acids flood the liver, and ketone bodies accumulate faster than peripheral tissues can consume them. The result is diabetic ketoacidosis (DKA) — a metabolic emergency of combined hyperglycemia, ketonemia, and acidosis. Type 1 typically presents acutely, often in childhood or young adulthood, and requires exogenous insulin indefinitely because no endogenous source remains.
Type 2 diabetes begins upstream: with insulin resistance. Target tissues — particularly skeletal muscle, liver, and adipose — respond poorly to insulin signaling. The beta cells compensate by producing more insulin, maintaining near-normal glucose for years at the cost of enormous secretory effort. Over time, beta cells exhaust and gradually fail. This progression — insulin resistance → compensatory hyperinsulinemia → beta cell exhaustion → overt hyperglycemia — is insidious. Patients may have significant metabolic dysfunction for a decade before diagnosis. Unlike Type 1, endogenous insulin is still present in early and moderate Type 2, which is why DKA is rare; instead, the risk is hyperosmolar hyperglycemic state, where extreme hyperglycemia causes osmotic fluid shifts without acidosis.
Both forms share the same final damage mechanism: chronic hyperglycemia drives microvascular and macrovascular complications. Glucose reacts non-enzymatically with proteins (glycation), forms advanced glycation end-products (AGEs), generates reactive oxygen species, and drives pathological changes in vessel walls. Small vessels (retina, kidney glomerulus, peripheral nerves) are particularly vulnerable, leading to retinopathy, nephropathy, and neuropathy. Large vessels develop accelerated atherosclerosis, raising the risk of heart attack and stroke. The HbA1c measurement — glycated hemoglobin — reflects average blood glucose over the preceding 2–3 months, providing a durable marker of how much glycemic stress tissues have endured. The central therapeutic principle in both types is the same: minimize the time spent in hyperglycemia to slow or prevent the complications that ultimately determine morbidity and mortality.